FREMONT, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seeking to expand the knowledge base surrounding spectral flow cytometry, Cytek Biosciences, Inc. (CTKB) (Nasdaq: CTKB), a leading cell analysis ...

The "Europe Flow Cytometry Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe flow cytometry market is projected to reach $2.04 billion by ...

As the fields of flow cytometry and spatial biology advance, researchers are uncovering exciting applications for the expanding data from their samples. Innovative reagents, fluidic and optical ...

Flow cytometry is a single-cell analytical technique that uses fluorophore-labeled cell structures or biomarkers to differentiate between cell populations. Through this method, researchers detect the ...

After five decades of use, flow cytometry is entrenched in biomedical science. Besides enabling the quick processing of cells in suspension, flow cytometry provides quantitative results across ...

Flow cytometry is an invaluable method for biomedical research. Since its development over 50 years ago, technology for flow cytometry has progressed rapidly, allowing for the detection of more and ...

Flow cytometry is crucial for diagnosing hematological malignancies. However, the rising number of tests and ongoing labor shortages are placing significant pressure on both the lab and its staff. Lab ...

FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster cellular insights, spectral flow cytometry leader Cytek Biosciences, Inc.

FREMONT, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- In a move that underscores its dedication to shaping the future of cell analysis, Cytek Biosciences, Inc. (CTKB) (Nasdaq: CTKB) today announced the ...

Cytometry and immune profiling have emerged as indispensable techniques in modern biomedical research. These methodologies enable the precise analysis of individual cells within heterogeneous ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...